Conversation with The Cancer Letter Rosenberg: Yescarta is going to be lifesaving for patients with lymphomas October 20, 2017Vol.43 No.39By Matthew Bin Han Ong
Conversation with The Cancer Letter UPMC’s Ferris: “Now there are more system-wide pressures to make a budget and to monitor quality” October 20, 2017Vol.43 No.39By Paul Goldberg
Conversation with The Cancer Letter Rubin: FDA helped Merck figure out how to channel science into regulatory approval October 13, 2017Vol.43 No.38By Paul Goldberg
Conversation with The Cancer Letter Lemery: “We saw consistent evidence of the drug’s response in multiple tumor types” October 13, 2017Vol.43 No.38By Paul Goldberg
Conversation with The Cancer LetterFree Allan Erickson: “I think Philip Morris has a long-term goal of a smoke-free world October 06, 2017Vol.43 No.37By Paul Goldberg
Conversation with The Cancer LetterFree Matt Myers: Philip Morris has a long history of funding what it calls independent research by previously credible researchers October 06, 2017Vol.43 No.37By Paul Goldberg
Conversation with The Cancer Letter Ashworth’s challenge: Build one very big data sharing system across the University of California cancer centers September 15, 2017Vol.43 No.34By Matthew Bin Han Ong
Conversation with The Cancer Letter The Next Step: Neil Hayes picks up stakes at UNC to build an NCI-designated cancer program in Memphis September 15, 2017Vol.43 No.34By Paul Goldberg
Conversation with The Cancer LetterFree Lowy: NCI’s intramural program made development of the HPV vaccine possible September 06, 2017Vol.43 No.33By Paul Goldberg
Conversation with The Cancer Letter More than three million life-years added over 60 years as a result of SWOG clinical trials August 08, 2017Vol.43 No.31By Claire Dietz
